Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CSPC Pharmaceutical
Biotech
AstraZeneca returns to China's CSPC for $18.5B obesity deal
AstraZeneca is handing $1.2 billion upfront to CSPC for the ex-China rights to the biopharma’s once-monthly injectable weight management portfolio.
James Waldron
Jan 30, 2026 4:50am
AstraZeneca pens $5.3B pact with CSPC to develop oral drugs
Jun 13, 2025 5:56am
Radiance joins ROR1 race, paying $15M for ADC to challenge Merck
Feb 19, 2025 7:32am
Corbus posts first US data on challenger to Pfizer's ADC Padcev
Feb 14, 2025 9:20am
BeiGene inks $150M deal to follow cancer trail blazed by Amgen
Dec 13, 2024 9:11am
AstraZeneca pays CSPC $100M for preclinical heart disease drug
Oct 7, 2024 6:12am
